An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding

References

• Agundez JA, Blanca M, Cornejo-Garcia JA, et al. Pharmacogenomics of cyclooxygenases. Pharmacogenomics. 2015;16(5):501–522.
   Google Scholar
• Grosser T, Theken KN, FitzGerald GA. Cyclooxygenase inhibition: pain, inflammation, and the cardiovascular system. Clin Pharmacol Ther. 2017 Oct;102(4):611–622.
   Google Scholar
• Diaz A, Chepenik KP, Korn JH, et al. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res. 1998 May 25;241(1):222–229.
   Google Scholar
• Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120.
   Google Scholar
• Lovell AR, Ernst ME. Drug-induced hypertension: focus on mechanisms and management. Curr Hypertens Rep. 2017 May;19(5):39.
   Google Scholar
• Ho KY, Gwee KA, Cheng YK, et al. Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice. J Pain Res. 2018;11:1937–1948.
   Google Scholar
• Khan S, Andrews KL, Chin-Dusting JPF. Cyclo-oxygenase (COX) inhibitors and cardiovascular risk: are non-steroidal anti-inflammatory drugs really anti-inflammatory? Int J Mol Sci. 2019 Aug 30;20:17.
   Google Scholar
• Radi ZA, Khan KN. Cardio-renal safety of non-steroidal anti-inflammatory drugs. J Toxicol Sci. 2019;44(6):373–391.
   Google Scholar
• Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S3.
   Google Scholar
• Graham DY, Opekun AR, Willingham FF, et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005 Jan;3(1):55–59.
   Google Scholar
• Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013 Oct;68(10):1219–1232.
   Google Scholar
• Cornejo-Garcia JA, Blanca-Lopez N, Dona I, et al. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Curr Drug Metab. 2009 Nov;10(9):971–980.
   Google Scholar
• Dona I, Blanca-Lopez N, Cornejo-Garcia JA, et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology. 2011 Jan;41(1):86–95.
   Google Scholar
• Cornejo-Garcia JA, Jagemann LR, Blanca-Lopez N, et al. Genetic variants of the arachidonic acid pathway in non-steroidal anti-inflammatory drug-induced acute urticaria. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology. 2012 Dec;42(12):1772–1781.
   Google Scholar
• Perez-Alzate D, Cornejo-Garcia JA, Perez-Sanchez N, et al. Immediate reactions to more than 1 NSAID must not be considered cross-hypersensitivity unless tolerance to ASA is verified. J Investig Allergol Clin Immunol. 2017;27(1):32–39.
   Google Scholar
• MDC P-S, Garcia-Martin E, Agundez JA, et al. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: an update on pharmacogenetics studies. Pharmacogenomics. 2018 Aug 1;19(13):1069–1086.
   Google Scholar
• Andrade RJ, Agundez JA, Lucena MI, et al. Pharmacogenomics in drug induced liver injury. Curr Drug Metab. 2009 Nov;10(9):956–970.
   Google Scholar
• Lucena MI, Garcia-Martin E, Daly AK, et al. Next-generation sequencing of PTGS genes reveals an increased frequency of non-synonymous variants among patients with NSAID-induced liver injury. Front Genet. 2019;10:134.
   Google Scholar
• Amo G, Cornejo-Garcia JA, Garcia-Menaya JM, et al. FCERI and histamine metabolism gene variability in selective responders to NSAIDS. Front Pharmacol. 2016;7:353.
   Google Scholar
• Perez-Alzate D, Blanca-Lopez N, Dona I, et al. Asthma and rhinitis induced by selective immediate reactions to paracetamol and non-steroidal anti-inflammatory drugs in aspirin tolerant subjects. Front Pharmacol. 2016;7:215.
   Google Scholar
• Amo G, Marti M, Garcia-Menaya JM, et al. Identification of novel biomarkers for drug hypersensitivity after sequencing of the promoter area in 16 genes of the vitamin d pathway and the high-affinity IgE receptor. Front Genet. 2019;10:582.
   Google Scholar
• Pachkoria K, Lucena MI, Ruiz-Cabello F, et al. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol. 2007 Mar;150(6):808–815.
   Google Scholar
• Agundez JA, Garcia-Martin E, Martinez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607–620.
   Google Scholar
• Garcia-Martin E, Martinez C, Tabares B, et al. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther. 2004 Aug;76(2):119–127.
   Google Scholar
• Martinez C, Garcia-Martin E, Blanco G, et al. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol. 2005 Jan;59(1):62–69.
   Google Scholar
• Mancy A, Antignac M, Minoletti C, et al. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264–14270.
   Google Scholar
• Martinez C, Andreu I, Amo G, et al. Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole. Biochem Pharmacol. 2014 Dec 1;92(3):457–466.
   Google Scholar
• Chang SY, Li W, Traeger SC, et al. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. Drug Metab Dispos. 2008 Dec;36(12):2513–2522.
   Google Scholar
• PharmVar cited 2019 Dec 12 Available from: https://www.pharmvar.org/gene/CYP2C9
   Google Scholar
• Garcia-Martin E, Martinez C, Ladero JM, et al. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006;10(1):29–40.
   Google Scholar
• Sandberg M, Yasar U, Stromberg P, et al. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol. 2002 Oct;54(4):423–429.
   Google Scholar
• Wang L, Bao SH, Pan PP, et al. Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm. 2015;41(8):1363–1367.
   Google Scholar
• Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol. 1997 Jul 1;54(1):33–41.
   Google Scholar
• Aoyama T, Ishida Y, Kaneko M, et al. Pharmacokinetics and pharmacodynamics of meloxicam in East Asian populations: the role of ethnicity on drug response. CPT Pharmacometrics Syst Pharmacol. 2017 Dec;6(12):823–832.
   Google Scholar
• Perini JA, Suarez-Kurtz G. Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther. 2006 Nov;80(5):549–551.
   Google Scholar
• Vianna-Jorge R, Perini JA, Rondinelli E, et al. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther. 2004 Jul;76(1):18–26.
   Google Scholar
• Wei L, Locuson CW, Tracy TS. Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol. 2007 Nov;72(5):1280–1288.
   Google Scholar
• Guo Y, Zhang Y, Wang Y, et al. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos. 2005 Jun;33(6):749–753.
   Google Scholar
• Lundblad MS, Ohlsson S, Johansson P, et al. Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3. Clin Pharmacol Ther. 2006 Mar;79(3):287–288.
   Google Scholar
• Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994 Feb;4(1):39–42.
   Google Scholar
• Romkes M, Faletto MB, Blaisdell JA, et al. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry. 1991 Apr 2;30(13):3247–3255.
   Google Scholar
• Martin JH, Begg EJ, Kennedy MA, et al. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br J Clin Pharmacol. 2001 Jun;51(6):627–630.
   Google Scholar
• Zarza J. Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9. Thromb Haemost. 2003 Jul;90(1):161–162.
   Google Scholar
• Martinez C, Blanco G, Ladero JM, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004 Jan;141(2):205–208.
   Google Scholar
• Vonkeman HE, van de Laar MA, van der Palen J, et al. Allele variants of the cytochrome P450 2C9 genotype in white subjects from the netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin Ther. 2006 Oct;28(10):1670–1676.
   Google Scholar
• Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007 Aug;133(2):465–471.
   Google Scholar
• Ma J, Yang XY, Qiao L, et al. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy. J Dig Dis. 2008 May;9(2):79–83.
   Google Scholar
• Blanco G, Martinez C, Ladero JM, et al. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics. 2008 Jan;18(1):37–43.
   Google Scholar
• Carbonell N, Verstuyft C, Massard J, et al. CYP2C9*3 loss-of-function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAIDs other than aspirin. Clin Pharmacol Ther. 2010 Jun;87(6):693–698.
   Google Scholar
• Musumba CO, Jorgensen A, Sutton L, et al. CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease. Clin Pharmacol Ther. 2013 Feb;93(2):195–203.
   Google Scholar
• Figueiras A, Estany-Gestal A, Aguirre C, et al. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. Pharmacogenet Genomics. 2016 Feb;26(2):66–73.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097.
   Google Scholar
• Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006 Jul;12(6):31.
   Google Scholar
• Agundez JA, Martinez C, Perez-Sala D, et al. Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009 Nov;10(9):998–1008.
   Google Scholar
• Kirchheiner J, Meineke I, Steinbach N, et al. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol. 2003 Jan;55(1):51–61.
   Google Scholar
• Malhi H, Atac B, Daly AK, et al. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgrad Med J. 2004 Feb;80(940):107–109.
   Google Scholar
• Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet. 1997 Sep;33(3):184–213.
   Google Scholar
• Agundez JA, Martinez C, Garcia-Martin E, et al. Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding. Gastroenterology. 2007 Dec;133(6):2071–2072.
   Google Scholar
• Lopez-Rodriguez R, Novalbos J, Gallego-Sandin S, et al. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol Res. 2008 Jul;58(1):77–84.
   Google Scholar
• Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the clinical pharmacogenetics implementation consortium (CPIC) guideline development process. Curr Drug Metab. 2014 Feb;15(2):209–217.
   Google Scholar
• Caudle KE, Rettie AE, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542–548.
   Google Scholar
• Johnson JA, Caudle KE, Gong L, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017 Sep;102(3):397–404.
   Google Scholar
• Kim E, Ihm C, Kang W. Modeling of aceclofenac metabolism to major metabolites in healthy volunteers. Drug Metab Pharmacokinet. 2016 Dec;31(6):458–463.
   Google Scholar
• Tang C, Shou M, Mei Q, et al. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453–459.
   Google Scholar
• Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet. 1995 Feb;28(2):100–114.
   Google Scholar
• Lucas S. The pharmacology of indomethacin. Headache. 2016 Feb;56(2):436–446.
   Google Scholar
• Gates BJ, Nguyen TT, Setter SM, et al. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother. 2005 Oct;6(12):2117–2140.
   Google Scholar
• Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994 Feb;26(2):107–120.
   Google Scholar
• Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet. 1998 Jun;34(6):421–428.
   Google Scholar
• Agundez JAG, Gomez-Tabales J, Ruano F, et al. The potential role of pharmacogenomics and biotransformation in hypersensitivity reactions to paracetamol. Curr Opin Allergy Clin Immunol. 2018 Aug;18(4):302–309.
   Google Scholar
• Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet. 1997 Apr;32(4):268–293.
   Google Scholar
• Takemoto JK, Reynolds JK, Remsberg CM, et al. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703–720.
   Google Scholar
• Gupta A, Zheng L, Ramanujam V, et al. Novel use of pharmacogenetic testing in the identification of CYP2C9 polymorphisms related to NSAID-induced gastropathy. Pain Med. 2015 May;16(5):866–869.
   Google Scholar
• Garcia-Martin E, Esguevillas G, Blanca-Lopez N, et al. Genetic determinants of metamizole metabolism modify the risk of developing anaphylaxis. Pharmacogenet Genomics. 2015 Sep;25(9):462–464.
   Google Scholar
• Plaza-Seron Mdel C, Ayuso P, Perez-Sanchez N, et al. Copy number variation in ALOX5 and PTGER1 is associated with NSAIDs-induced urticaria and/or angioedema. Pharmacogenet Genomics. 2016 Jun;26(6):280–287.
   Google Scholar
• Agundez JA, Lucena MI, Martinez C, et al. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2011 7; Jul(7): 817–828.
   Google Scholar
• Agundez JA, Gonzalez-Alvarez DL, Vega-Rodriguez MA, et al. Gene variants and haplotypes modifying transcription factor binding sites in the human cyclooxygenase 1 and 2 (PTGS1 and PTGS2) genes. Curr Drug Metab. 2014 Feb;15(2):182–195.
   Google Scholar
• Bigler J, Whitton J, Lampe JW, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001 May 1;61(9):3566–3569.
   Google Scholar
• Martinez C, Garcia-Martin E, Ladero JM, et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis. 2001 Aug;22(8):1323–1326.
   Google Scholar
• Wang H, Ren L, He Y, et al. Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case-control studies. Tumour Biol. 2014 May;35(5):4317–4322.
   Google Scholar
• Sachse C, Smith G, Wilkie MJ, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis. 2002 Nov;23(11):1839–1849.
   Google Scholar
• Chan AT, Tranah GJ, Giovannucci EL, et al. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol. 2004 Aug;2(8):704–712.
   Google Scholar
• Landi S, Gemignani F, Moreno V, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics. 2005 Aug;15(8):535–546.
   Google Scholar
• McGreavey LE, Turner F, Smith G, et al. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics. 2005 Oct;15(10):713–721.
   Google Scholar
• Liao LH, Zhang H, Lai MP, et al. The association of CYP2C9 gene polymorphisms with colorectal carcinoma in han Chinese. Clin Chim Acta. 2007 May 1;380(1–2):191–196.
   Google Scholar
• Kury S, Buecher B, Robiou-du-Pont S, et al. Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1460–1467.
   Google Scholar
• Cotterchio M, Boucher BA, Manno M, et al. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3098–3107.
   Google Scholar
• Chan AT, Zauber AG, Hsu M, et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009 Jun;136(7):2127–2136 e1.
   Google Scholar
• Northwood EL, Elliott F, Forman D, et al. Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics. 2010 May;20(5):315–326.
   Google Scholar
• Sainz J, Rudolph A, Hein R, et al. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer. 2011 Apr;18(2):265–276.
   Google Scholar
• Liang S, Hu J, Cao W, et al. Meta-analysis of cytochrome P-450 2C9 polymorphism and colorectal cancer risk. PloS One. 2012;7(11):e49134.
   Google Scholar
• Ladero JM, Agundez JA, Martinez C, et al. Analysis of the functional polymorphism in the cytochrome P450 CYP2C8 gene rs11572080 with regard to colorectal cancer risk. Front Genet. 2012;3:278.
   Google Scholar
• Zhao Y, Han Y, Zhang L, et al. Quantitative assessment of the effect of cytochrome P450 2C9 gene polymorphism and colorectal cancer. PloS One. 2013;8(4):e60607.
   Google Scholar
• Ozhan G, Mutur M, Ercan G, et al. Genetic variations in the xenobiotic-metabolizing enzymes CYP1A1, CYP1A2, CYP2C9, CYP2C19 and susceptibility to colorectal cancer among Turkish people. Genet Test Mol Biomarkers. 2014 Apr;18(4):223–228.
   Google Scholar
• Tranah GJ, Chan AT, Giovannucci E, et al. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the nurses’ health study and the physicians’ health study. Mol Carcinog. 2005 Sep;44(1):21–30.
   Google Scholar
• Samowitz WS, Wolff RK, Curtin K, et al. Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol. 2006 Jul;4(7):894–901.
   Google Scholar
• Siemes C, Eijgelsheim M, Dieleman JP, et al. No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype. Neth J Med. 2009 Apr;67(4):134–141.
   Google Scholar
• Cleary SP, Cotterchio M, Shi E, et al. Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol. 2010 Nov 1;172(9):1000–1014.
   Google Scholar
• Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015;11:1061–1075.
   Google Scholar
• Moore N, Charlesworth A, Van Ganse E, et al. Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiol Drug Saf. 2003 Oct-Nov;12(7):601–610.
   Google Scholar
• Kaufman DW, Kelly JP, Wiholm BE, et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol. 1999 Nov;94(11):3189–3196.
   Google Scholar
• Food, Drug Administration HHS. Organ-specific warnings; internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final monograph. final rule. Fed Regist. 2009 Apr 29;74(81):19385–19409.
   Google Scholar
• Martinez C, Galvan S, Garcia-Martin E, et al. Variability in ethanol biodisposition in whites is modulated by polymorphisms in the ADH1B and ADH1C genes. Hepatology. 2010 Feb;51(2):491–500.
   Google Scholar